SCHEMBL23705196

SCHEMBL23705196

CC1(C)O[C@@H]2[C@H](O1)[C@H](N1CCOC1=O)CO[C@@H]2COCCOCCOCCOCCBr

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26880187 0.98 — —
SCHEMBL26880186 0.87 — —
SCHEMBL26880184 0.86 — —
SCHEMBL26902550 0.84 DPP4 (0.30) —
SCHEMBL26880189 0.79 — —
SCHEMBL23705041 0.59 CDA (0.36) —
SCHEMBL24256513 0.59 CDA (0.36) —
SCHEMBL24256523 0.58 HTR1A (0.39) —
SCHEMBL26880060 0.58 ASGR1 (0.31) —
SCHEMBL26902373 0.58 ASGR1 (0.31) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4097138-A1 ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS Avila Therapeutics, Inc. (US) 2022-12-07 — — EP disclosed
WO-2021155317-A1 ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS AVILAR THERAPEUTICS, INC. (US) 2021-08-05 — — WO disclosed
Send feedback